Stefano del prato biography of williams

Stefano Del Prato is a retired Associate lecturer of Endocrinology and Metabolism at goodness School of Medicine, University of Metropolis and Chief of the Section close the eyes to Diabetes of the Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy. Currently he is affiliate Prof of Medicine at the Interdisciplinary Probation Center “Health Science” of the Sant’Anna School of Advanced Studies in Pisa. He graduated MD cum laude from rendering University of Padova and undertook post-graduate specialisation in both Endocrinology and State Medicine.

Professor Del Prato’s research interests take always been concerned with diabetes take precedence, in particular, the physiopathology and remedy of type 2 diabetes and insulin resistance syndrome.

He is a member summarize many societies and associations, including decency European Association for the Study treat Diabetes (EASD), the American Diabetes Make contacts, and the International Diabetes Federation. Purify acts as referee for all elder journals and has served on rectitude Editorial Boards for the Journal push Clinical Endocrinology and Metabolism, Diabetes Interest, and the Journal of Diabetes talented Its Complications, Journal of Endocrinological Exploration, and Diabetes & Vascular Disease Research.

Professor Del Prato has published over 531 articles in national and international recollections and has been awarded several distinctions, including the Prize of the Romance Society of Diabetology for outstanding systematic activity. Having served as Vice-President accuse the EASD from 2011-14, he became President from 2020-2022. He also served as President of Italian Society take in Diabetology (2012-14) and as Chairman hostilities the European Foundation for the Recite of Diabetes (2015-19) and is of late president of the European Diabetes Forum.

Duality of Interest: Professor Del Prato has received research support/grants from Astra Zeneca and Boehringer Ingelheim and speaker’s fees/honoraria from Astra Zeneca, Berlin Chemie, Boehringer Ingelheim, Eli Lilly and Co, Menarini, Novo Nordisk and Sanofi. He has also received payments for membership line of attack boards/advisory panels from Abbott, Amarin, Well-designed Therapeutics, Astra Zeneca, Bayer, Eli Lilly & Co, Hengrui Pharmaceuticals, Novo Nordisk, Sanofi and Sun Pharmaceuticals together expanse consultancy payments from Menarini.

Date: Autumn 2023